Key Deadline Approaches for Sage Therapeutics Investors
Attention investors! A crucial deadline is fast approaching for those involved in the ongoing class action lawsuit against Sage Therapeutics, Inc. This litigation impacts individuals who purchased or acquired Sage securities during a specified period. As the date draws near, it's essential to stay informed about your rights and options.
Details of the Class Action Lawsuit
As investors in Sage Therapeutics, you should be aware that the deadline to file a lead plaintiff motion is set for October 28, 2024. This legal action involves those who purchased Sage Therapeutics securities between specified dates. If you have suffered financial losses during this period, it is pertinent to understand the proceedings and get the support you may need.
Recent Developments Affecting Sage's Stock
Recently, Sage Therapeutics has faced several setbacks, contributing to declines in stock price. In early August 2023, the company revealed that the FDA had approved its drug zuranolone solely for postpartum depression (PPD) and not for major depressive disorder (MDD), which was a significant blow to investor confidence. Following the announcement, Sage's stock price plummeted over 53%, damaging the financial standing of many investors.
Impact of Phase 2 Study Results
Furthermore, disappointing results from clinical trials have compounded challenges for the company. In April 2024, Sage disclosed that SAGE-718, a drug aimed at mild cognitive impairment due to Parkinson's Disease, failed to meet its primary study endpoint. This led to a further decline in stock price, falling nearly 20% in one day.
Understanding the Allegations
The complaint filed in the class action lawsuit asserts that Sage's leadership made false and misleading statements throughout the class period. Key assertions include allegations that the effectiveness of zuranolone in treating MDD was overstated, as were the prospects of both SAGE-718 and SAGE-324 for their respective conditions.
What Investors Should Do Now
If you are a current or former investor in Sage Therapeutics and believe you may have been misled, it's vital to explore your options. Engaging with legal counsel can provide clarity and guide you through the process of potentially recovering losses due to the recent upheaval in the stock's performance.
Contact Information for Investors
For investors looking for more information on their legal rights, Charles H. Linehan of Glancy Prongay & Murray LLP is available for support. You can reach GPM at their Los Angeles office or via the provided contact information. It’s beneficial to take proactive steps to safeguard your investments and assert your rights.
Frequently Asked Questions
1. What is the significance of the October 28, 2024 deadline?
This date marks the last opportunity for impacted investors to file a lead plaintiff motion in the class action lawsuit regarding Sage Therapeutics.
2. Why did Sage Therapeutics’ stock price decline recently?
Declines were due to disappointing FDA approvals and unfavorable clinical trial results, which did not meet the expectations set by the company.
3. How can I learn more about my rights as an investor?
You can contact legal professionals specializing in securities law to better understand your rights and options within the class action framework.
4. Who should consider joining the class action lawsuit?
Investors who purchased Sage Therapeutics securities during the specified class period and suffered financial losses should consider participating.
5. What steps can I take to recover losses?
It is advisable to seek legal counsel, who can help you navigate the class action process and advise on the appropriate actions to take for recovery.
